GlassScriptPhysician profile
Simone Christine Martin
NPI 1558709832
$2,166.51
in general payments reported to CMS, 2019-2025
32 companies · $454 in 2025
The $454 reported for 2025 was more than what 75% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $680 · 2022: $365 · 2023: $371 · 2024: $296 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.11 |
| Education | $133.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $340.06 | 2021-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $322.23 | 2021-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $259.75 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $181.39 | 2021-2025 | |
| Myovant Sciences INC. | $123.91 | 2021-2022 | |
| Procept Biorobotics Corporation | $123.66 | 2022-2024 | Aquabeam System |
| Coloplast Corp | $97.55 | 2021-2025 | |
| Pfizer INC. | $67.46 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $61.64 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.12 | 2021-2024 | |
| Urogen Pharma, INC. | $47.92 | 2025 | |
| Endo Pharmaceuticals INC. | $42.47 | 2021-2022 | |
| Blue Earth Diagnostics | $38.89 | 2021-2022 | |
| Teleflex LLC | $37.71 | 2021-2023 | Urolift |
| Isoray, INC | $36.09 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.63 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $28.91 | 2021 | |
| Tolmar, INC. | $27.91 | 2023 | |
| Amgen INC. | $27.22 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $26.99 | 2021 | |
| Urovant Sciences INC | $24.26 | 2022 | |
| Laborie Medical Technologies Corp. | $20.31 | 2025 | |
| Medtronic, INC. | $18.00 | 2021 | |
| Boston Scientific Corporation | $17.65 | 2025 | Spaceoar Vue System - 10ml |
| Travere Therapeutics, INC. | $16.45 | 2022 | |
| 180 Medical, INC. | $15.60 | 2021 | |
| Rochester Medical Corporation | $15.23 | 2021 | |
| Foundation Medicine, INC. | $14.84 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.14 | 2022 | |
| Endo USA, INC. | $13.35 | 2024 | Xiaflex |
| Merck Sharp & Dohme LLC | $12.17 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.